Grace Therapeutics, Inc.
GRCE Healthcare Biotechnology
In the quarter to June 2026, EPS fell 333.3% and free cash flow fell 78.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.
Follow GRCE
Grace Therapeutics, Inc. (GRCE) EV/Sales
As of 16 October 2026, Grace Therapeutics, Inc. (GRCE) trades at a EV/Sales of 109×. Over the past ten years it has ranged from −85.0× (December 2022) to 27,374× (December 2019); the current reading is higher than 35% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2021 | 66.5× | (89.62%) |
| FY2016 | 640× | 1,799.15% |
| FY2016 | 33.7× | (80.09%) |
| FY2015 | 169× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2021 | 66.5× | (27.76%) |
| Dec 2020 | 92.0× | (92.96%) |
| Nov 2016 | 1,308× | 83.40% |
| Aug 2016 | 713× | 0.35% |
| 6 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ANVS Annovis Bio, Inc. compare | n/m |
| ALDX Aldeyra Therapeutics, Inc. compare | n/m |
| DWTX Dogwood Therapeutics, Inc compare | n/m |
| VERU Veru Inc. compare | 1.2× |
| SGMOQ Sangamo Therapeutics, Inc. compare | 1.2× |
| CELU Celularity, Inc. compare | 4.1× |
| GRCE Grace Therapeutics, Inc. | 109× |
| TIL Instil Bio, Inc. compare | 401× |
| LBPS 4D pharma PLC Sponsored ADR compare | — |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)